| P50 | author | Carl H. June | Q19277113 |
| | Simon F Lacey | Q56978267 |
| | Bruce L. Levine | Q85544154 |
| P2093 | author name string | Yan Li | |
| | Andrew H Ko | |
| | Alan P Venook | |
| | Lawrence Fong | |
| | J Joseph Melenhorst | |
| | Lloyd Damon | |
| | Margaret Tempero | |
| | Gregory L Beatty | |
| | Gabriela Plesa | |
| | Mark H O'Hara | |
| | Alexander C Jordan | |
| | Evan Tooker | |
| | Renee B Chang | |
| P2860 | cites work | Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients | Q24598792 |
| | T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 |
| | Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials | Q27312288 |
| | B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas | Q33776937 |
| | Current concepts in the diagnosis and management of cytokine release syndrome | Q33886879 |
| | Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors | Q34052580 |
| | FcRgamma activation regulates inflammation-associated squamous carcinogenesis. | Q34859537 |
| | B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis | Q35081453 |
| | Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells | Q35202343 |
| | Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. | Q35587352 |
| | Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma | Q35598804 |
| | Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T | Q35798161 |
| | Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates | Q36183567 |
| | Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy | Q36349583 |
| | Robust enumeration of cell subsets from tissue expression profiles | Q36539395 |
| | PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. | Q36868333 |
| | CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | Q36951727 |
| | Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy | Q37117624 |
| | Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. | Q37117781 |
| | Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology | Q37257207 |
| | Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo | Q37386167 |
| | T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. | Q37466219 |
| | Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. | Q37599478 |
| | Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor | Q38473933 |
| | PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression. | Q38790070 |
| | Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. | Q38808099 |
| | Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps | Q38845812 |
| | Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. | Q39655872 |
| | HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial | Q40234446 |
| | Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | Q41429394 |
| | The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity | Q42657377 |
| | Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 |
| | B cell-regulated immune responses in tumor models and cancer patients | Q42969728 |
| | A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. | Q45946525 |
| | De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent | Q46068963 |
| | Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors | Q46119758 |
| | IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia | Q47098673 |
| | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | Q49029195 |
| | Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. | Q51736472 |
| | Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. | Q52699883 |
| | Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. | Q52715364 |
| | Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. | Q52767783 |
| | Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia | Q57059971 |
| | Chimeric Antigen Receptor Therapy | Q89419402 |
| | Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities | Q91124496 |
| | Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL | Q91278266 |
| | Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy | Q91385826 |
| | A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial | Q92396870 |
| | Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines | Q92526117 |
| | Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers | Q92666841 |
| | Tertiary lymphoid structures improve immunotherapy and survival in melanoma | Q92669545 |
| | B cells and tertiary lymphoid structures promote immunotherapy response | Q92669559 |
| | B cells are associated with survival and immunotherapy response in sarcoma | Q92669566 |
| | Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle | Q92744972 |
| P577 | publication date | 2020-07-21 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer | |